Fortress Biotech, Inc. Repayments of Long-Term Debt
Fortress Biotech, Inc. (FBIO) had Repayments of Long-Term Debt of $51.40 million as of 2024-07-25, per its 10-Q filed 2025-11-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2025-11-14
- 2024-07-25: Repayments of Long-term Debt $51.40M.
| Period end | Repayments of Long-term Debt |
|---|---|
| 2024-07-25 | $51.40M 10-Q · filed 2025-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |